Notice Pursuant to the National Cooperative Research and Production Act of 1993-Medical Technology Enterprise Consortium, 22119-22120 [2016-08574]

Agencies

• Antitrust Division
• Department of Justice

[Federal Register Volume 81, Number 72 (Thursday, April 14, 2016)]
[Notices]
[Pages 22119-22120]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-08574]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Antitrust Division


Notice Pursuant to the National Cooperative Research and 
Production Act of 1993--Medical Technology Enterprise Consortium

    Notice is hereby given that, on March 15, 2016, pursuant to Section 
6(a) of the National Cooperative Research and

[[Page 22120]]

Production Act of 1993, 15 U.S.C. 4301 et seq. (``the Act''), the 
Medical Technology Enterprise Consortium (``MTEC'') has filed written 
notifications simultaneously with the Attorney General and the Federal 
Trade Commission disclosing changes in its membership and nature and 
objectives. The notifications were filed for the purpose of extending 
the Act's provisions limiting the recovery of antitrust plaintiffs to 
actual damages under specified circumstances. Specifically, Agile 
Immersive, Arlington, VA; Armed Forces Institute for Regenerative 
Medicine (AFIRM), Winston-Salem, NC; Articulate Biomedical, LLC, 
Ithaca, NY; BioMed SA, San Antonio, TX; Cedars-Sinai Medical Center, 
Los Angeles, CA; CUBRC, Inc., Buffalo, NY; Eagle Applied Sciences, LLC, 
San Antonio, TX; East Carolina University, Greenville, NC; FirstString 
Research, Inc., Mt. Pleasant, SC; Gateway Biotechnology, Inc., Kent, 
OH; General Electric Company, Global Research, Niskayuna, NY; Georgia 
Tech Research Corporation, Atlanta, GA; IDIQ, Inc., Fallbrook, CA; 
InnoVital Systems, Inc., Beltsville, MD; Johns Hopkins University, 
Baltimore, MD; and Kestrel Corporation, Albuquerque, NM, Lovelace 
Biomedical and Environmental Research Institute, Albuquerque, NM; 
McAllister & Quinn, LLC, Washington, DC; Medical University of South 
Carolina, Charleston, SC; MedPro Technologies, Inc., San Antonio, TX; 
Michigan Technological University, Houghton, MI; MicroCures, Inc., 
Santa Cruz, CA; MiMedx Group, Inc., Marietta, GA; New York Institute of 
Technology, Old Westbury, NY; North American Rescue, LLC, Greer, SC; 
Otologic Pharmaceutics, Inc., Oklahoma City, OK; Pertexa Healthcare 
Technologies, Inc., Ridgecrest, CA; Qool Therapeutics, Inc., Menlo 
Park, CA; RegenMed Development Organization, Winston-Salem, NC; 
Resiliency Technologies, Inc., Spartanburg, SC; Second Sight Medical 
Products, Inc., Sylmar, CA; Southwest Research Institute, San Antonio, 
TX; Techline Technologies, Inc., Willow Grove, PA; The Conafay Group, 
Washington, DC; The General Hospital Corporation dba Massachusetts 
General Hospital, Boston, MA; The Henry M. Jackson Foundation for the 
Advancement of Military Medicine, Bethesda, MD; The Ohio State 
University, Columbus, OH; The Research Foundation for the State 
University of New York (SUNY), Syracuse, NY; The University of Texas at 
Arlington Research Institute (UTARI), Arlington, TX; Trideum 
Biosciences, Frederick, MD; Triton Systems, Inc., Chelmsford, MA; 
University of Illinois at Chicago, Chicago, IL; University of Miami, 
Coral Gables, FL; University of Michigan, Ann Arbor, MI; University of 
Nebraska Medical Center, Omaha, NE; University of Pittsburgh, 
Pittsburgh, PA; University of South Carolina, Columbia, SC; University 
of Virginia, Charlottesville, VA; Vanderbilt University School of 
Engineering, Nashville, TN; Wake Forest University Health Sciences, 
Winston-Salem, NC; and Weinberg Medical Physics, LLC, North Bethesda, 
MD, have been added as parties to this venture.
    Also, Biohealth Innovation, Inc., Rockville, MD; Center for 
Integration of Medicine and Innovative Technology (CIMIT), Boston, MA; 
Florida Atlantic University, Boca Raton, FL; Indiana University, 
Bloomington, IN; Institute for Systems Biology, Seattle, WA; Jade 
Therapeutics, Inc., Salt Lake City, UT; Johns Hopkins Technology 
Transfer, Baltimore, MD; KAI Research, Inc. (KAI), Rockville, MD; Human 
Effects Modeling, Advanced Technology, Inc., L-3 Communications, San 
Diego, CA; Maryland Technology Development Corp. (TEDCO), Columbia, MD; 
and Institute for Collaborative Biotechnologies, University of 
California, Santa Barbara, CA, have withdrawn as parties to this 
venture.
    The general areas of MTEC's planned activity are to: (a) enter into 
an Other Transactions Agreement with the U.S. Army Medical Research and 
Materiel Command (the Government) to fund certain research, 
development, and commercialization efforts conducted in partnership 
with the Government, the Consortium, and Consortium Members that 
enhance the medical knowledge and life cycle management of the medical 
program, and enable the Government to better protect, treat, and 
optimize Warfighter health and performance across the full spectrum of 
operations; (b) participate in establishing sound technical and 
programmatic performance goals based on the needs and requirements of 
the Government's Technology Objectives and other mission requirements; 
(c) create programs and secure funding; (d) provide a unified voice 
that effectively articulates the strategically important role military 
medical technologies play in current and future military operations; 
and (e) maximize use of Government and member capabilities and 
resources for developing critical processes, procedures, drugs, 
vaccines, and devices that can be transitioned and commercialized for 
both military and civilian use.
    No other changes have been made in either the membership or planned 
activity of the group research project. Membership in this group 
research project remains open, and MTEC intends to file additional 
written notifications disclosing all changes in membership.
    On May 9, 2014, MTEC filed its original notification pursuant to 
Section 6(a) of the Act. The Department of Justice published a notice 
in the Federal Register pursuant to Section 6(b) of the Act on June 9, 
2014 (79 FR 32999).

Patricia A. Brink,
Director of Civil Enforcement, Antitrust Division.
[FR Doc. 2016-08574 Filed 4-13-16; 8:45 am]
 BILLING CODE P